Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIS trial of first-line venetoclax + obinutuzumab with MRD-tailored venetoclax-based continuation in young high-risk CLL
2022-002579-12Phase 2Active
- Sponsor
- GIMEMA
- Start
- Nov 2022
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of venetoclax, obinutuzumab and zanubrutinib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (3 arms), sponsored by GIMEMA. Primary endpoint: Rate of undetectable minimal residual disease at end of combination therapy. Started Nov 2022; status: active.
02
Drugs
venetoclaxobinutuzumabzanubrutinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2022-002579-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002579-12.